8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 13, 2026·SEC
Castle Biosciences, Inc.(CSTL)Earnings, Financials & Key Ratios
CSTL•NASDAQ
$24.75
$750M mkt cap·Price updated May 6, 2026
AboutCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.Show more
- Revenue$344M+3.7%
- EBITDA-$2M-108.3%
- Net Income-$24M-232.4%
- EPS (Diluted)-0.83-233.9%
- Gross Margin68.66%-16.1%
- EBITDA Margin-0.59%-108.0%
- Operating Margin-12.44%-576.3%
- Net Margin-7.02%-227.7%
- ROE-5.21%-221.0%
- ROIC-8.52%-539.2%
- Debt/Equity0.08+35.6%
- Interest Coverage-342.19-991.7%
CSTL Key Insights
Castle Biosciences, Inc. (CSTL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 40.6%
✗Weaknesses
- ✗Profits declining 18.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CSTL Price & Volume
Castle Biosciences, Inc. (CSTL) stock price & volume — 10-year historical chart
Loading chart...
CSTL Growth Metrics
Castle Biosciences, Inc. (CSTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years40.6%
3 Years35.94%
TTM-2.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-153.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-126.5%
Return on Capital
10 Years-35%
5 Years-9.97%
3 Years-7.77%
Last Year-8.63%
CSTL Recent Earnings
Castle Biosciences, Inc. (CSTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q1 2026Latest
Feb 26, 2026EPS
$0.08
Est $0.23
+65.2%
Revenue
$87M
Est $80M
+8.9%
Q4 2025
Nov 3, 2025EPS
$0.02
Est $0.34
+94.1%
Revenue
$83M
Est $80M
+3.3%
Q3 2025
Aug 4, 2025EPS
$0.15
Est $0.51
+129.4%
Revenue
$86M
Est $68M
+26.7%
Q2 2025
May 5, 2025EPS
$0.20
Est $0.08
-150.0%
Revenue
$88M
Est $72M
+22.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.08vs $0.23+65.2% | $87Mvs $80M+8.9% |
| Q4 2025 | Nov 3, 2025 | $0.02vs $0.34+94.1% | $83Mvs $80M+3.3% |
| Q3 2025 | Aug 4, 2025 | $0.15vs $0.51+129.4% | $86Mvs $68M+26.7% |
| Q2 2025 | May 5, 2025 | $0.20vs $0.08-150.0% | $88Mvs $72M+22.5% |
Based on last 12 quarters of dataView full earnings history →
CSTL Peer Comparison
Castle Biosciences, Inc. (CSTL) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 | |
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 GH | 11.53B | 92.25 | -27.79 | 32.88% | -44.18% | |||
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 |
Compare CSTL vs Peers
Castle Biosciences, Inc. (CSTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CSTL Income Statement
Castle Biosciences, Inc. (CSTL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 13.75M | 22.79M | 51.87M | 62.65M | 94.08M | 137.04M | 219.79M | 332.07M | 344.23M | 339.92M |
| Revenue Growth % | - | 65.67% | 127.62% | 20.79% | 50.18% | 45.65% | 60.38% | 51.09% | 3.66% | -2.06% |
| Cost of Goods Sold | 4.92M | 5.3M | 7.31M | 9.69M | 15.82M | 32.01M | 44.98M | 60.2M | 107.88M | 91.5M |
| COGS % of Revenue | 35.79% | 23.25% | 14.09% | 15.46% | 16.82% | 23.36% | 20.47% | 18.13% | 31.34% | - |
| Gross Profit | 8.83M▲ 0% | 17.49M▲ 98.0% | 44.55M▲ 154.8% | 52.96M▲ 18.9% | 78.26M▲ 47.8% | 105.03M▲ 34.2% | 174.81M▲ 66.4% | 271.86M▲ 55.5% | 236.35M▼ 13.1% | 164.74M▲ 0% |
| Gross Margin % | 64.21% | 76.75% | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | 81.87% | 68.66% | 48.46% |
| Gross Profit Growth % | - | 98.02% | 154.76% | 18.87% | 47.77% | 34.2% | 66.43% | 55.52% | -13.06% | - |
| Operating Expenses | 19.73M | 21.32M | 37.23M | 59.51M | 118.34M | 177.88M | 242.78M | 263.19M | 279.16M | 281.71M |
| OpEx % of Revenue | 143.46% | 93.59% | 71.78% | 94.98% | 125.78% | 129.81% | 110.46% | 79.26% | 81.1% | - |
| Selling, General & Admin | 15.26M | 16.47M | 29.84M | 48.13M | 86.74M | 143M | 180.15M | 200.05M | 229.32M | 235.6M |
| SG&A % of Revenue | 110.94% | 72.28% | 57.54% | 76.83% | 92.19% | 104.35% | 81.97% | 60.24% | 66.62% | - |
| Research & Development | 4.47M | 4.85M | 7.38M | 13.26M | 29.65M | 44.9M | 53.62M | 52.04M | 51.85M | 53.69M |
| R&D % of Revenue | 32.52% | 21.3% | 14.24% | 21.16% | 31.51% | 32.77% | 24.4% | 15.67% | 15.06% | - |
| Other Operating Expenses | 163.29K | 0 | 0 | -1.88M | 1.96M | -10.02M | 9.01M | 11.11M | -2.02M | 2M |
| Operating Income | -10.9M▲ 0% | -3.84M▲ 64.8% | 7.33M▲ 291.1% | -6.54M▼ 189.3% | -40.08M▼ 512.6% | -72.86M▼ 81.8% | -67.98M▲ 6.7% | 8.67M▲ 112.8% | -42.81M▼ 593.8% | -14.88M▲ 0% |
| Operating Margin % | -79.25% | -16.83% | 14.13% | -10.44% | -42.6% | -53.16% | -30.93% | 2.61% | -12.44% | -4.38% |
| Operating Income Growth % | - | 64.81% | 291.05% | -189.27% | -512.64% | -81.78% | 6.7% | 112.75% | -593.77% | - |
| EBITDA | -10.59M | -3.51M | 7.69M | -6.07M | -36.67M | -62.31M | -55.65M | 24.67M | -2.04M | -2.06M |
| EBITDA Margin % | -76.99% | -15.42% | 14.82% | -9.69% | -38.98% | -45.47% | -25.32% | 7.43% | -0.59% | -0.61% |
| EBITDA Growth % | - | 66.83% | 318.81% | -178.97% | -504.15% | -69.92% | 10.7% | 144.33% | -108.27% | -107.19% |
| D&A (Non-Cash Add-back) | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M | 40.77M | 12.82M |
| EBIT | -10.71M | -4.08M | 9.92M | -7.57M | -40.01M | -68.89M | -57.35M | 22.14M | -29.43M | -3.2M |
| Net Interest Income | -1.62M | -2.25M | -4.26M | -2.26M | 67K | 3.95M | 10.61M | 12.34M | 11.69M | 8.6M |
| Interest Income | 26.18K | 23.51K | 312K | 373K | 68K | 3.97M | 10.62M | 12.92M | 11.77M | 11.22M |
| Interest Expense | 1.65M | 2.27M | 4.57M | 2.63M | 1K | 17K | 11K | 577K | 86K | -65K |
| Other Income/Expense | -1.46M | -2.52M | -1.98M | -3.66M | 67K | 3.95M | 10.61M | 12.89M | 13.3M | 11.64M |
| Pretax Income | -12.36M▲ 0% | -6.36M▲ 48.6% | 5.35M▲ 184.1% | -10.2M▼ 290.7% | -40.01M▼ 292.3% | -68.9M▼ 72.2% | -57.37M▲ 16.7% | 21.56M▲ 137.6% | -29.51M▼ 236.9% | -17.66M▲ 0% |
| Pretax Margin % | -89.86% | -27.91% | 10.31% | -16.28% | -42.53% | -50.28% | -26.1% | 6.49% | -8.57% | -5.19% |
| Income Tax | 9.73K | 8.61K | 72K | 84K | -8.72M | -1.77M | 101K | 3.32M | -5.36M | -4.82M |
| Effective Tax Rate % | -0.08% | -0.14% | 1.35% | -0.82% | 21.79% | 2.56% | -0.18% | 15.39% | 18.15% | 27.32% |
| Net Income | -12.37M▲ 0% | -6.37M▲ 48.5% | 5.28M▲ 182.9% | -10.28M▼ 294.9% | -31.29M▼ 204.3% | -67.14M▼ 114.6% | -57.47M▲ 14.4% | 18.25M▲ 131.7% | -24.16M▼ 232.4% | -12.83M▲ 0% |
| Net Margin % | -89.93% | -27.94% | 10.17% | -16.42% | -33.26% | -48.99% | -26.15% | 5.49% | -7.02% | -3.77% |
| Net Income Growth % | - | 48.53% | 182.88% | -294.88% | -204.28% | -114.55% | 14.41% | 131.75% | -232.41% | -153.15% |
| Net Income (Continuing) | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M | -12.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.26▲ 0% | -0.60▲ 52.4% | -0.21▲ 65.0% | -0.54▼ 157.1% | -1.24▼ 129.6% | -2.58▼ 108.1% | -2.14▲ 17.1% | 0.62▲ 129.0% | -0.83▼ 233.9% | -0.43▲ 0% |
| EPS Growth % | - | 52.38% | 65% | -157.14% | -129.63% | -108.06% | 17.05% | 128.97% | -233.87% | -126.5% |
| EPS (Basic) | -1.26 | -0.60 | 0.35 | -0.54 | -1.24 | -2.58 | -2.14 | 0.66 | -0.83 | - |
| Diluted Shares Outstanding | 9.78M | 10.65M | 8.66M | 18.93M | 25.14M | 26.05M | 26.8M | 29.25M | 28.99M | 29.89M |
| Basic Shares Outstanding | 9.78M | 10.65M | 8.58M | 18.93M | 25.14M | 26.05M | 26.8M | 27.78M | 28.99M | 29.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CSTL Balance Sheet
Castle Biosciences, Inc. (CSTL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.68M | 18.13M | 116.68M | 429.59M | 353.74M | 292.29M | 295.63M | 360.15M | 361.1M | 328.9M |
| Cash & Short-Term Investments | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 258.63M | 243.1M | 293.13M | 299.5M | 261.69M |
| Cash Only | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M | 63.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 135.68M | 144.26M | 173.42M | 182.78M | 197.92M |
| Accounts Receivable | 4.65M | 12.09M | 14.65M | 12.76M | 17.28M | 23.48M | 38.3M | 51.22M | 43.38M | 42.26M |
| Days Sales Outstanding | 123.46 | 193.67 | 103.09 | 74.34 | 67.05 | 62.53 | 63.61 | 56.3 | 46 | 50.32 |
| Inventory | 304.58K | 882.23K | 1.24M | 2.22M | 2.02M | 3.98M | 7.94M | 8.13M | 10.25M | 10.46M |
| Days Inventory Outstanding | 22.59 | 60.79 | 61.77 | 83.55 | 46.62 | 45.38 | 64.44 | 49.32 | 34.69 | 37.63 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 6.21M | 6.29M | 7.67M | 7.96M | 14.49M |
| Total Non-Current Assets | 3.14M | 4.28M | 3.06M | 9.73M | 108.83M | 155.04M | 157.71M | 171.08M | 217.46M | 218.9M |
| Property, Plant & Equipment | 1.47M | 1.53M | 2.06M | 7.1M | 16.88M | 26.5M | 37.74M | 62.71M | 112.24M | 115.36M |
| Fixed Asset Turnover | 9.36x | 14.90x | 25.18x | 8.82x | 5.57x | 5.17x | 5.82x | 5.30x | 3.07x | 3.26x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 10.69M | 10.69M | 10.69M | 99.57M | 0 |
| Intangible Assets | 40.12K | 4.17K | 0 | 0 | 88.92M | 115.66M | 106.64M | 95.54M | 0 | 0 |
| Long-Term Investments | 1.56M | 2.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.63M | 2.75M | 1M | 2.63M | 3.02M | 2.2M | 2.63M | 2.15M | 5.65M | 17.55M |
| Total Assets | 9.82M▲ 0% | 22.4M▲ 128.1% | 119.75M▲ 434.5% | 439.33M▲ 266.9% | 462.57M▲ 5.3% | 447.33M▼ 3.3% | 453.34M▲ 1.3% | 531.24M▲ 17.2% | 578.56M▲ 8.9% | 547.8M▲ 0% |
| Asset Turnover | 1.40x | 1.02x | 0.43x | 0.14x | 0.20x | 0.31x | 0.48x | 0.63x | 0.59x | 0.61x |
| Asset Growth % | - | 128.15% | 434.46% | 266.88% | 5.29% | -3.3% | 1.34% | 17.18% | 8.91% | 39.25% |
| Total Current Liabilities | 5.22M | 6.74M | 15.29M | 20.88M | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M | 48.76M |
| Accounts Payable | 1.12M | 1.45M | 1.86M | 2.1M | 2.55M | 4.73M | 10.27M | 6.9M | 18.71M | 15.04M |
| Days Payables Outstanding | 82.82 | 99.99 | 93.12 | 79.07 | 58.73 | 53.95 | 83.32 | 41.84 | 63.3 | 58.98 |
| Short-Term Debt | 1M | 0 | 5.83M | 0 | 0 | 0 | 0 | 278K | 1.74M | 2.92M |
| Deferred Revenue (Current) | 9.73K | 0 | 0 | 6.62M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 706.64K | 6M | 10M | 16.91M | 25.67M | 30.69M | 774K | 48.22M | 45.84M |
| Current Ratio | 1.28x | 2.69x | 7.63x | 20.58x | 14.21x | 8.09x | 6.20x | 7.29x | 5.26x | 5.26x |
| Quick Ratio | 1.22x | 2.56x | 7.55x | 20.47x | 14.13x | 7.98x | 6.04x | 7.13x | 5.11x | 5.11x |
| Cash Conversion Cycle | 63.23 | 154.47 | 71.73 | 78.82 | 54.93 | 53.96 | 44.73 | 63.78 | 17.39 | 28.97 |
| Total Non-Current Liabilities | 18.87M | 25.74M | 19.34M | 2.76M | 25.95M | 12.05M | 14.4M | 26.01M | 39.01M | 37.63M |
| Long-Term Debt | 17.6M | 24.5M | 19.29M | 0 | 0 | 0 | 0 | 9.74M | 35.17M | 33.8M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 7.02M | 11.62M | 14.2M | 14.66M | 0 | 51.38M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 635K | 428K | 206K | 1.61M | 2.33M | 7.79M |
| Other Non-Current Liabilities | 1.27M | 1.24M | 55K | 1.03M | 18.29M | 0 | 0 | 0 | 1.5M | 9.24M |
| Total Liabilities | 24.09M | 32.47M | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M | 75.4M | 107.68M | 86.39M |
| Total Debt | 18.6M | 24.5M | 25.12M | 0 | 8.2M | 13.4M | 15.34M | 26.34M | 36.91M | 36.72M |
| Net Debt | 17.39M | 20.02M | -73.72M | -409.85M | -321.43M | -109.55M | -83.51M | -93.36M | -79.82M | -27.04M |
| Debt / Equity | - | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x | 0.08x | 0.08x |
| Debt / EBITDA | - | - | 3.27x | - | - | - | - | 1.07x | - | -17.83x |
| Net Debt / EBITDA | - | - | -9.59x | - | - | - | - | -3.79x | - | 13.13x |
| Interest Coverage | -6.49x | -1.80x | 2.17x | -2.87x | -40011.00x | -4052.18x | -5214.00x | 38.37x | -342.19x | 49.20x |
| Total Equity | -14.27M▲ 0% | -10.07M▲ 29.4% | 85.11M▲ 945.3% | 415.69M▲ 388.4% | 411.74M▼ 1.0% | 399.15M▼ 3.1% | 391.27M▼ 2.0% | 455.83M▲ 16.5% | 470.87M▲ 3.3% | 461.42M▲ 0% |
| Equity Growth % | - | 29.44% | 945.28% | 388.4% | -0.95% | -3.06% | -1.97% | 16.5% | 3.3% | 21.41% |
| Book Value per Share | -1.46 | -0.95 | 9.83 | 21.96 | 16.38 | 15.32 | 14.60 | 15.58 | 16.24 | 15.44 |
| Total Shareholders' Equity | -14.27M | -10.07M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.83M | 470.87M | 461.42M |
| Common Stock | 1.9K | 1.92K | 17K | 25K | 25K | 27K | 27K | 28K | 30K | 30K |
| Retained Earnings | -51.12M | -57.49M | -52.21M | -62.5M | -93.77M | -160.91M | -218.37M | -200.13M | -224.28M | -238.81M |
| Treasury Stock | -809.6K | -2.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -638.47K | -909.38K | 0 | 0 | 0 | -381K | 136K | 230K | 267K | -63K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CSTL Cash Flow Statement
Castle Biosciences, Inc. (CSTL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.23M | -12.29M | 7.01M | 9.87M | -18.98M | -41.66M | -5.63M | 64.87M | 64.35M | 64.35M |
| Operating CF Margin % | -88.95% | -53.96% | 13.53% | 15.75% | -20.18% | -30.4% | -2.56% | 19.53% | 18.69% | - |
| Operating CF Growth % | - | -0.5% | 157.06% | 40.63% | -292.43% | -119.43% | 86.49% | 1252.97% | -0.8% | -272.35% |
| Net Income | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M | -12.83M |
| Depreciation & Amortization | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M | 40.77M | 14.94M |
| Stock-Based Compensation | 108.7K | 293.64K | 1.25M | 8.31M | 21.74M | 36.32M | 51.22M | 50.32M | 45.89M | 44.49M |
| Deferred Taxes | -163.29K | 272.42K | -2.28M | 0 | -8.74M | -1.88M | -223K | 1.4M | -6.23M | -5.47M |
| Other Non-Cash Items | 520.23K | 542.37K | 2.37M | 2.22M | 0 | -19.5M | -4.86M | -6.97M | -5.53M | -26.85M |
| Working Capital Changes | -640.51K | -7.36M | 44K | 9.15M | -4.1M | -7K | -6.63M | -14.13M | 13.6M | 33.98M |
| Change in Receivables | -428.21K | -8.41M | -896K | 1.66M | -4.63M | -6.22M | -14.93M | -12.64M | 6.88M | 13.17M |
| Change in Inventory | -115.56K | -577.66K | -355K | -980K | 327K | -1.68M | -3.96M | -193K | -2.14M | -3.63M |
| Change in Payables | 370.9K | 197.25K | 557K | 169K | -182K | 582K | 5.71M | -4.37M | 3.08M | 5.66M |
| Cash from Investing | -494.85K | -277.04K | -937K | -4.75M | -66.66M | -166.54M | -16.18M | -50.14M | -60.37M | -63.74M |
| Capital Expenditures | -494.85K | -277.04K | -937K | -4.75M | -3.48M | -5.63M | -13.62M | -28.33M | -36.02M | -43.74M |
| CapEx % of Revenue | 3.6% | 1.22% | 1.81% | 7.58% | 3.7% | 4.11% | 6.2% | 8.53% | 10.46% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -26.97M | 0 | 18K | -18.73M | -18.71M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 3K | -63.17M | 742K | 13K | 0 | -7.64M | -2.09M |
| Cash from Financing | 8.87M | 15.84M | 88.29M | 305.89M | 5.42M | 1.51M | -2.3M | 6.14M | -6.96M | -10.44M |
| Debt Issued (Net) | 8.57M | 5.42M | 20.92M | -27.36M | -8K | -122K | -142K | 9.9M | -115K | -115K |
| Equity Issued (Net) | 289.16K | 10.42M | 65.98M | 330.04M | 0 | 0 | 0 | 2.02M | 2.21M | 2.19M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.55K | 0 | 1.39M | 3.21M | 5.43M | 1.64M | -2.16M | -5.78M | -9.05M | -12.51M |
| Net Change in Cash | -3.86M▲ 0% | 3.27M▲ 184.6% | 94.37M▲ 2788.9% | 311.01M▲ 229.6% | -80.22M▼ 125.8% | -206.69M▼ 157.7% | -24.11M▲ 88.3% | 20.87M▲ 186.6% | -2.98M▼ 114.3% | 27.04M▲ 0% |
| Free Cash Flow | -12.73M▲ 0% | -12.57M▲ 1.2% | 6.08M▲ 148.3% | 5.11M▼ 15.9% | -22.47M▼ 539.3% | -47.29M▼ 110.5% | -19.25M▲ 59.3% | 36.54M▲ 289.8% | 28.33M▼ 22.5% | 4.52M▲ 0% |
| FCF Margin % | -92.54% | -55.17% | 11.72% | 8.16% | -23.88% | -34.51% | -8.76% | 11% | 8.23% | 1.33% |
| FCF Growth % | - | 1.23% | 148.35% | -15.86% | -539.3% | -110.48% | 59.3% | 289.85% | -22.48% | -89.18% |
| FCF per Share | -1.30 | -1.18 | 0.70 | 0.27 | -0.89 | -1.81 | -0.72 | 1.25 | 0.98 | 0.98 |
| FCF Conversion (FCF/Net Income) | 0.99x | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x | -2.66x | -0.35x |
| Interest Paid | 0 | 1.64M | 2.21M | 1.98M | 1K | 16K | 11K | 434K | 0 | 0 |
| Taxes Paid | 0 | 160K | 150K | 102K | 16K | 120K | 198K | 2.5M | 0 | 0 |
CSTL Key Ratios
Castle Biosciences, Inc. (CSTL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | 14.06% | -4.11% | -7.56% | -16.56% | -14.54% | 4.31% | -5.21% | -2.77% |
| Return on Invested Capital (ROIC) | -44.02% | 51.5% | -56.96% | -62.53% | -28.77% | -17.07% | 1.94% | -8.52% | -8.52% |
| Gross Margin | 76.75% | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | 81.87% | 68.66% | 48.46% |
| Net Margin | -27.94% | 10.17% | -16.42% | -33.26% | -48.99% | -26.15% | 5.49% | -7.02% | -3.77% |
| Debt / Equity | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x | 0.08x | 0.08x |
| Interest Coverage | -1.80x | 2.17x | -2.87x | -40011.00x | -4052.18x | -5214.00x | 38.37x | -342.19x | 49.20x |
| FCF Conversion | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x | -2.66x | -0.35x |
| Revenue Growth | 65.67% | 127.62% | 20.79% | 50.18% | 45.65% | 60.38% | 51.09% | 3.66% | -2.06% |
CSTL SEC Filings & Documents
Castle Biosciences, Inc. (CSTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
CSTL Frequently Asked Questions
Castle Biosciences, Inc. (CSTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Castle Biosciences, Inc. (CSTL) reported $339.9M in revenue for fiscal year 2025. This represents a 2371% increase from $13.8M in 2017.
Castle Biosciences, Inc. (CSTL) grew revenue by 3.7% over the past year. Growth has been modest.
Castle Biosciences, Inc. (CSTL) reported a net loss of $12.8M for fiscal year 2025.
Dividend & Returns
Castle Biosciences, Inc. (CSTL) has a return on equity (ROE) of -5.2%. Negative ROE indicates the company is unprofitable.
Castle Biosciences, Inc. (CSTL) generated $4.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CSTL
Castle Biosciences, Inc. (CSTL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates